NL
GSK icon

NWAM LLC’s GSK GSK Stock Holding History

NWAM LLC’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$795K Buy
15,159
+1,828
+14% +$96.7K 0.04% 365
2026
Q1 		$736K Buy
13,331
+534
+4% +$28.9K 0.04% 334
2025
Q4 		$644K Buy
12,797
+117
+0.9% +$5.46K 0.04% 353
2025
Q3 		$559K Sell
12,680
-660
-5% -$25.8K 0.03% 389
2025
Q2 		$496K Buy
13,340
+921
+7% +$35.2K 0.03% 398
2025
Q1 		$481K Buy
12,419
+3,499
+39% +$128K 0.04% 320
2024
Q4 		$302K Sell
8,920
-6,365
-42% -$229K 0.02% 481
2024
Q3 		$625K Buy
+15,285
New +$625K 0.04% 340
2024
Q2 		– Sell
-16,080
Closed -$710K – 304
2024
Q1 		$710K Buy
16,080
+8,976
+126% +$370K 0.06% 272
2023
Q4 		$263K Sell
7,104
-1,719
-19% -$61.7K 0.02% 467
2023
Q3 		$320K Buy
8,823
+1,246
+16% +$44.2K 0.03% 368
2023
Q2 		$270K Buy
7,577
+1,345
+22% +$48.2K 0.02% 440
2023
Q1 		$222K Buy
+6,232
New +$218K 0.02% 434
2017
Q4 		– Sell
-4,558
Closed -$231K – 332
2017
Q3 		$231K Buy
+4,558
New +$231K 0.06% 273
2017
Q2 		– Sell
-5,561
Closed -$293K – 330
2017
Q1 		$293K Buy
+5,561
New +$282K 0.09% 221
2016
Q4 		– Sell
-5,832
Closed -$314K – 296
2016
Q3 		$314K Buy
+5,832
New +$320K 0.02% 192
2015
Q2 		– Sell
-5,146
Closed -$297K – 259
2015
Q1 		$297K Sell
5,146
-7
-0.1% -$401 0.13% 170
2014
Q4 		$275K Sell
5,153
-498
-9% -$27.9K 0.12% 169
2014
Q3 		$325K Buy
5,651
+621
+12% +$38.1K 0.12% 183
2014
Q2 		$336K Buy
5,030
+186
+4% +$12.6K 0.1% 192
2014
Q1 		$324K Buy
4,844
+1,719
+55% +$116K 0.11% 168
2013
Q4 		$209K Sell
3,125
-201
-6% -$13K 0.11% 150
2013
Q3 		$209K Sell
3,326
-12
-0.4% -$772 0.1% 170
2013
Q2 		$209K Buy
+3,338
New +$212K 0.11% 170

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

NWAM LLC's GSK Position: Q2 2026 in Review

NWAM LLC increased its GSK (GSK) stake by 14% in Q2 2026, buying an estimated $96.7K and bringing the position to 15,159 shares worth $795K. The position accounts for 0.04% of the portfolio, ranked #365.

NWAM LLC first reported a position in GSK in Q2 2013 and has held it in 24 quarters since. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • NWAM LLC held 15,159 shares of GSK worth $795K as of Q2 2026.
  • NWAM LLC bought 1,828 GSK shares in Q2 2026, an estimated $96.7K.
  • GSK made up 0.04% of NWAM LLC's portfolio in Q2 2026, its #365 holding.
  • NWAM LLC first reported a position in GSK in Q2 2013 and has held it in 24 quarters since.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on NWAM LLC's 13F filing for Q2 2026, filed 23 Jul 2026.